Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

FULC Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Fulcrum Therapeutics, Inc.NASDAQ: FULC

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 76.22M shares rose 22.0% year over year, ahead of the +9.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 20.3% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.0% holds above the trailing-twelve-month pace of +9.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
76.22M+20.3% QoQ
Last fiscal yearDec 2025
63.36M+2.2% YoY
LTMMar 2026
66.18M+9.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.0%——
1 year+2.2%——
3-year CAGR+12.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
63.36M USD
Year-over-year change
+2.2%
4-year CAGR
+15.7%

Weighted Avg Shares vs competitors

How FULC compares with its peers on the latest reported figures

  • FULC's LTM Mar 2026 weighted avg shares of 66.18M shares is the 8th highest of the 10 companies compared; the peer median is 161.95M shares.
  • Its year-over-year change of +9.8% is the 7th highest of 10, against a peer median of +12.1%.
  • Over three fiscal years its annual growth of +12.1% compares with a peer median of +14.5%.
FULC Competitors Peer median
Weighted Avg Shares for FULC and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.59M +6.8%+29.9%
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026233.09M +16.0%+10.7%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
FULCFulcrum Therapeutics, Inc.LTM Mar 202666.18M +9.8%+12.1%
OMEROmeros CorporationLTM Mar 202665.07M +12.1%+0.4%
NGNENeurogene Inc.LTM Mar 202620M +14.7%+18.2%
Peer median (excluding FULC) 161.95M+12.1%+14.5%

Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.16M6.34M2.81M80M0
Cost of Revenue69.7M76.78M71.8M63.39M1.39M
Gross Profit(50.54M)(70.44M)(69M)16.61M(1.39M)
Gross Margin-263.7%-1110.7%-2459.8%20.8%—
Research & Development69.7M76.78M71.8M63.39M56.1M
Selling, General & Admin30.52M41.69M41.67M36.45M28.67M
Operating Expenses30.52M42.12M41.67M38.51M83.38M
Depreciation & Amortization2.52M2.41M2.17M1.59M1.39M
EBITDA(78.33M)(109.72M)(95.16M)(18.24M)(73.49M)
EBITDA Margin-408.8%-1730.1%-3392.6%-22.8%—
Operating Income(81.05M)(112.56M)(110.66M)(21.9M)(84.77M)
Operating Margin-423.0%-1774.9%-3945.2%-27.4%—
Interest Income207K0000
Interest Expense00000
Other Income / Expenses207K2.69M13.33M12.17M9.89M
Income Before Tax(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Pre-Tax Margin-421.9%-1732.4%-3470.1%-12.2%—
Income Tax Expense00000
Net Income(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Net Margin-421.9%-1732.4%-3470.1%-12.2%—
EPS (Basic)(2.22)(2.35)(1.59)(0.16)(1.18)
EPS (Diluted)(2.22)(2.35)(1.59)(0.16)(1.18)
Weighted Avg Shares35.36M44.99M61.31M61.98M63.36M
Weighted Avg Shares (Diluted)35.36M44.99M61.31M61.98M63.36M

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Intrinsic Alpha fair value

Locked

Current Price

$3.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.